All News

Officials with the FDA have approved AstraZeneca’s dapagliflozin, saxagliptin and metformin hydrochloride (Qternmet XR) extended release tablets for adults with type 2 diabetes.

The drug application was granted the FDA’s Priority Review designation, as well as a Tropical Disease Priority Review Voucher under a program intended to encourage development of new drugs and biologics for the prevention and treatment of certain tropical diseases.